Second, the case of Valeant, the drugmaker that so engorged itself with so many acquisitions that it ballooned into a $  bubble.   In 2007, the company hired a new CEO, one J. Michael Pearson, fresh from the McKinsey consulting group.   Pearson had no medical or scientific background, but, according to a January 13 report in New York magazine, he offered something more precious to Valeant shareholders.   He had a "blunt," "brutal," even "radical" business philosophy: namely, cut RD to the bone and raise prices 